Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | TACR3 | P29371 | 9/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | REN | P00797 | 2/20 | 0.32 |
| ▸ | CTSA | P10619 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.31 |
| ▸ | ITGAV | P06756 | 3/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1718525 | 0.90 | TACR3 (0.46) | TACR3CYP2C9 | |
| SCHEMBL1719163 | 0.82 | REN (0.37) | REN | |
| SCHEMBL1718774 | 0.76 | TACR3 (0.46) | TACR3TOP2ACYP2C9 | |
| SCHEMBL1718129 | 0.76 | TACR3 (0.47) | TACR3RENCYP2C9 | |
| SCHEMBL1717621 | 0.75 | TACR3 (0.46) | TACR3TOP2AMAPTCYP2C9 | |
| SCHEMBL1717956 | 0.75 | TACR3 (0.45) | TACR3RENCYP2C9 | |
| SCHEMBL1717668 | 0.75 | TACR3 (0.46) | TACR3TOP2AMAPTCYP2C9 | |
| SCHEMBL8175965 | 0.75 | PIK3CD (0.42) | SLC6A2TACR3TOP2APIK3CDPIK3R1 | |
| SCHEMBL4754548 | 0.74 | TACR3 (0.51) | TACR3TOP2ACYP2C9 | |
| SCHEMBL1717827 | 0.74 | TACR3 (0.45) | TACR3CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173639-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-05-08 | — | — | US | disclosed |
| US-20090143402-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143402-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNQ3, KCNK3, GRIK3 | SLC6A2 143/4885TACR3 30/4885TOP2A 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.